Ernest Gallo Clinic and Research Center       At the University of California, San Francisco
About Research & Faculty News Careers & Training Institute for Molecular Neuroscience NIAAA Center (ACTG) Contact Search
RESEARCH & FACULTY
Core Facilities
Genomics Resources
Research Faculty

Dorit Ron's Lab

Somayeh Ahmadiantehrani
Segev Barak
Emmanuel Darcq
Sami Ben Hamida
Ky Phamluong
Feng Liu
Jun Wang
Vincent Warnault
Su Wu
Wendy Zhu

Segev Barak, PhD

Postdoctoral Fellow
Lab Member Since: 2009
Research Interests: Growth factors and alcohol addiction
Approach: Behavioral
Phone: (510) 985-3190
Email: sbarak@gallo.ucsf.edu

Publications:

Barak S., Ben Hamida S. (2012). Memory erasure, enhanced extinction and disrupted reconsolidation. Journal of Neuroscience 32(7):2250 –2251

Davies D.L., Bortolato M., Finn D., Ramaker M.J., Barak S., Ron D., Liang J., Olsen R.W. Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcoholism: Clinical and Experimental Research. In Press

Barak S, Ahmadiantehrani S., Kharazia V., Ron, D. (2011). Positive autoregulatory feedback loop of GDNF in the ventral tegmental area: implications for alcohol abuse disorders. Translational Psychiatry (2011) 1 (e60): 1-9

Barak S, Ahmadiantehrani S, Kharazia V and Ron D. Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption. Transl Psychiatry. In Press

Barak S., Carnicella S., Yowell Q.V., Ron D. (2011). Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. Journal of Neuroscience, 31(27):9885-9894

Gibb S.L., Jeanblanc J., Barak S., Yowell Q.V., Yaka R. and Ron D. (2011). Lyn kinase regulates mesolimbic dopamine release: implication for alcohol reward. Journal of Neuroscience, 31(6):2180-2187

Barak S., Weiner I. (2011) Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacology, Biochemistry and Behavior, 99(2): 164-189

Wang J., Carnicella S., Ahmadiantehrani S., He D.Y., Barak S., Kharazia V., Ben Hamida S., Zapata A., Shippenberg T.S., Ron, D. (2010). Nucleus accumbens-derived GDNF is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. Journal of Neuroscience, 30(43):14502-14512

Barak S., Weiner I (2011). The M1/M4 preferring antagonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: A selectively nonselective compound that can target multiple symptom domains of schizophrenia? International Journal of Neuropsychopharmacology

Black M.D., Stevens R.J., Rogacki N., Featherstone R.E., Senyah Y., Giardino O., Borowsky B., temmelin J., Cohen C., Pichat Ph., Arad M., Barak S., De Levie A. Weiner I., Griebel G., Varty G.B. (2011). AVE1625, a Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for Schizophrenia: Improvement in Cognitive Function and Reduction of Antipsychotic-Side Effects in Rodents. Psychopharmacology, 215(1):149-63

Barak S. (2009). Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behavioural Brain Research, 204(2):335-51

Barak S., Weiner I. (2010) Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli. Neuropsychopharmacology, 35: 1073-1082

Barak S., Weiner I (2010). Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology 209(2): 175-184

Barak S., Arad M., De Levie A., Black M.D., Griebel G., Weiner I. (2009). Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology, 34 (7): 1753-1763

Barak S., Weiner I. (2009). Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. International Journal of Neuropsychopharmacology, 12(2): 227-241

Black M., Varty GB., Arad M., Barak S., De Levie A., Boulay D., Pichat Ph., Griebel G., Weiner I. (2009). Procognitive and antipsychotic efficacy of Glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia. Latent inhibition studies in the rat. Psychopharmacology, 202(1-3): 385-396

Dresner E., Barak S. (2009). Effects of visual spatial structure on textual conversational multitasking. Communication Quarterly 57(1): 104-115

Barak S., Weiner I. (2007). Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 32(5): 989-999

Dresner E., Barak S. (2006). Conversational multitasking in interactive written discourse as a communication competence. Communication Reports 19(1): 70-78

CONTACT US
5858 Horton Street, Suite 200
Emeryville, CA 94608
Phone: (510) 985-3109

Clinical Studies l Webmail